Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Chloroquine Inhibits the Release of Inflammatory Cytokines by Human Lung Explants

Grassin-Delyle et al., Clinical Infectious Diseases, doi:10.1093/cid/ciaa546
May 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
On human lung parenchymal explants, CQ concentration clinically achievable in the lung (100µM) inhibited the lipopolysaccharide-induced release of TNF-ɑ (by 76%), IL-6 (by 68%), CCL2 (by 72%), and CCL3 (by 67%). In addition to antiviral activity, CQ may also mitigate the cytokine storm associated with severe pneumonia caused by coronaviruses.
Grassin-Delyle et al., 8 May 2020, peer-reviewed, 8 authors.
Ex Vivo studies are an important part of preclinical research, however results may be very different in vivo.
This PaperHCQAll
Stanislas Grassin-Delyle, Hélène Salvator, Marion Brollo, Emilie Catherinot, Edouard Sage, Louis-Jean Couderc, Emmanuel Naline, Professor Philippe Devillier
doi:10.1093/cid/ciaa546/5831983
On human lung parenchymal explants, chloroquine concentration clinically achievable in the lung (100 M) inhibited the lipopolysaccharide-induced release of TNF-by 76%), IL-6 (by 68%), CCL2 (by 72%) and CCL3 (by 67%). Beside its antiviral activity, chloroquine might also mitigate the cytokine storm associated with severe pneumonia caused by coronaviruses.
A c c e p t e d M a n u s c r i p t 8 of 100 µM according to the lung-to-blood ratio in the pharmacokinetic model [12] . Hence, chloroquine treatment would preferably be initiated in the first days of lung symptoms caused by SARS-CoVs; first to reduce viral replication and then to mitigate the cytokine storm that typically occurs a few days later in last-stage disease. Given that chloroquine and hydroxychloroquine both appear to affect cytokine production by human monocytes and to accumulate in the lung in a similar way, they might exert the same effect on the cytokine storm [9, 12] . Although the in vitro effects on
References
-Buenestado, Chaumais, Grassin-Delyle, Risse, Naline et al., Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma, PLoS One
-Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.105938
-Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends
-Mcchesney, Banks, Jr, Fabian, Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat, Toxicol Appl Pharmacol
-Mehta, Mcauley, Brown, Sanchez, Tattersall et al., HLH COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet
-Mzayek, Deng, Mather, Wasilevich, Liu et al., Randomized dose-ranging controlled trial of AQ-13, a candidate
-Schrezenmeier, Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol
-Wang, Yang, Li, Wen, Zhang, Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China, Clin Infect Dis
-Yao, Ye, Zhang, Cui, Huang et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Channappanavar, Perlman, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin Immunopathol
Grassin-Delyle, Salvator, Mantov, Abrial, Brollo et al., Bitter Taste Receptors (TAS2Rs) in Human Lung Macrophages: Receptor Expression and Inhibitory Effects of TAS2R Agonists, Front Physiol
Huang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J, doi:10.1093/cid/ciaa546/5831983byUppsalaUniversitetsbibliotekuser
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
{ 'DOI': '10.1093/cid/ciaa546', 'ISSN': ['1058-4838', '1537-6591'], 'URL': 'http://dx.doi.org/10.1093/cid/ciaa546', 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>On human lung parenchymal explants, chloroquine concentration ' 'clinically achievable in the lung (100 µM) inhibited the lipopolysaccharide-induced release ' 'of TNF-ɑ (by 76%), IL-6 (by 68%), CCL2 (by 72%), and CCL3 (by 67%). Besides its antiviral ' 'activity, chloroquine might also mitigate the cytokine storm associated with severe pneumonia ' 'caused by coronaviruses.</jats:p>', 'author': [ { 'affiliation': [ { 'name': 'Department of Respiratory Diseases, Foch Hospital, Suresnes, ' 'France'}, { 'name': 'INSERM Infection and Inflammation, Département de Biotechnologie ' 'de la Santé, University Paris-Saclay, Montigny-le-Bretonneux, ' 'France'}], 'family': 'Grassin-Delyle', 'given': 'Stanislas', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Department of Respiratory Diseases, Foch Hospital, Suresnes, ' 'France'}, { 'name': 'Laboratory of Research in Respiratory Pharmacology, Exhalomics ' 'Facility, Foch Hospital, University Paris-Saclay, Suresnes, ' 'France'}], 'family': 'Salvator', 'given': 'Hélène', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Laboratory of Research in Respiratory Pharmacology, Exhalomics ' 'Facility, Foch Hospital, University Paris-Saclay, Suresnes, ' 'France'}], 'family': 'Brollo', 'given': 'Marion', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Respiratory Diseases, Foch Hospital, Suresnes, ' 'France'}], 'family': 'Catherinot', 'given': 'Emilie', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Respiratory Diseases, Foch Hospital, Suresnes, ' 'France'}, {'name': 'UMR0892, INR AE, University Paris-Saclay, Jouy-en-Josas, France'}], 'family': 'Sage', 'given': 'Edouard', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Respiratory Diseases, Foch Hospital, Suresnes, ' 'France'}, { 'name': 'Laboratory of Research in Respiratory Pharmacology, Exhalomics ' 'Facility, Foch Hospital, University Paris-Saclay, Suresnes, ' 'France'}], 'family': 'Couderc', 'given': 'Louis-Jean', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Respiratory Diseases, Foch Hospital, Suresnes, ' 'France'}, { 'name': 'Laboratory of Research in Respiratory Pharmacology, Exhalomics ' 'Facility, Foch Hospital, University Paris-Saclay, Suresnes, ' 'France'}], 'family': 'Naline', 'given': 'Emmanuel', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-6054-1886', 'affiliation': [ { 'name': 'Department of Respiratory Diseases, Foch Hospital, Suresnes, ' 'France'}, { 'name': 'Laboratory of Research in Respiratory Pharmacology, Exhalomics ' 'Facility, Foch Hospital, University Paris-Saclay, Suresnes, ' 'France'}], 'authenticated-orcid': False, 'family': 'Devillier', 'given': 'Philippe', 'sequence': 'additional'}], 'container-title': 'Clinical Infectious Diseases', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2020, 5, 5]], 'date-time': '2020-05-05T11:11:36Z', 'timestamp': 1588677096000}, 'deposited': { 'date-parts': [[2020, 11, 19]], 'date-time': '2020-11-19T12:36:35Z', 'timestamp': 1605789395000}, 'indexed': {'date-parts': [[2024, 2, 29]], 'date-time': '2024-02-29T00:41:53Z', 'timestamp': 1709167313615}, 'is-referenced-by-count': 9, 'issue': '16', 'issued': {'date-parts': [[2020, 5, 8]]}, 'journal-issue': { 'issue': '16', 'published-online': {'date-parts': [[2020, 5, 8]]}, 'published-print': {'date-parts': [[2020, 11, 19]]}}, 'language': 'en', 'license': [ { 'URL': 'https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 5, 8]], 'date-time': '2020-05-08T00:00:00Z', 'timestamp': 1588896000000}}], 'link': [ { 'URL': 'http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa546/33563468/ciaa546.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/cid/article-pdf/71/16/2265/34393069/ciaa546.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/cid/article-pdf/71/16/2265/34393069/ciaa546.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '286', 'original-title': [], 'page': '2265-2268', 'prefix': '10.1093', 'published': {'date-parts': [[2020, 5, 8]]}, 'published-online': {'date-parts': [[2020, 5, 8]]}, 'published-other': {'date-parts': [[2020, 10, 15]]}, 'published-print': {'date-parts': [[2020, 11, 19]]}, 'publisher': 'Oxford University Press (OUP)', 'reference': [ { 'DOI': '10.1007/s00281-017-0629-x', 'article-title': 'Pathogenic human coronavirus infections: causes and consequences of ' 'cytokine storm and immunopathology', 'author': 'Channappanavar', 'doi-asserted-by': 'crossref', 'first-page': '529', 'journal-title': 'Semin Immunopathol', 'key': '2020111907070828500_CIT0001', 'volume': '39', 'year': '2017'}, { 'DOI': '10.1016/S0140-6736(20)30628-0', 'article-title': 'COVID-19: consider cytokine storm syndromes and immunosuppression.', 'author': 'Mehta', 'doi-asserted-by': 'crossref', 'first-page': '1033', 'journal-title': 'Lancet', 'key': '2020111907070828500_CIT0002', 'volume': '395', 'year': '2020'}, { 'DOI': '10.1016/S0140-6736(20)30183-5', 'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in ' 'Wuhan, China', 'author': 'Huang', 'doi-asserted-by': 'crossref', 'first-page': '497', 'journal-title': 'Lancet', 'key': '2020111907070828500_CIT0003', 'volume': '395', 'year': '2020'}, { 'article-title': 'Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, ' 'China', 'author': 'Wang', 'journal-title': 'Clin Infect Dis', 'key': '2020111907070828500_CIT0004', 'year': '2020'}, { 'DOI': '10.5582/bst.2020.01047', 'article-title': 'Breakthrough: chloroquine phosphate has shown apparent efficacy in ' 'treatment of COVID-19 associated pneumonia in clinical studies', 'author': 'Gao', 'doi-asserted-by': 'crossref', 'first-page': '72', 'journal-title': 'Biosci Trends', 'key': '2020111907070828500_CIT0005', 'volume': '14', 'year': '2020'}, { 'DOI': '10.1016/j.ijantimicag.2020.105938', 'article-title': 'New insights on the antiviral effects of chloroquine against ' 'coronavirus: what to expect for COVID-19?', 'author': 'Devaux', 'doi-asserted-by': 'crossref', 'journal-title': 'Int J Antimicrob Agents', 'key': '2020111907070828500_CIT0006', 'year': '2020'}, { 'DOI': '10.1186/1743-422X-2-69', 'article-title': 'Chloroquine is a potent inhibitor of SARS coronavirus infection and ' 'spread', 'author': 'Vincent', 'doi-asserted-by': 'crossref', 'first-page': '69', 'journal-title': 'Virol J', 'key': '2020111907070828500_CIT0007', 'volume': '2', 'year': '2005'}, { 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'author': 'Wang', 'doi-asserted-by': 'crossref', 'first-page': '269', 'journal-title': 'Cell Res', 'key': '2020111907070828500_CIT0008', 'volume': '30', 'year': '2020'}, { 'DOI': '10.1038/s41584-020-0372-x', 'article-title': 'Mechanisms of action of hydroxychloroquine and chloroquine: ' 'implications for rheumatology', 'author': 'Schrezenmeier', 'doi-asserted-by': 'crossref', 'first-page': '155', 'journal-title': 'Nat Rev Rheumatol', 'key': '2020111907070828500_CIT0009', 'volume': '16', 'year': '2020'}, { 'DOI': '10.3389/fphys.2019.01267', 'article-title': 'Bitter taste receptors (TAS2Rs) in human lung macrophages: receptor ' 'expression and inhibitory effects of TAS2R agonists', 'author': 'Grassin-Delyle', 'doi-asserted-by': 'crossref', 'first-page': '1267', 'journal-title': 'Front Physiol', 'key': '2020111907070828500_CIT0010', 'volume': '10', 'year': '2019'}, { 'DOI': '10.1016/0041-008X(67)90089-0', 'article-title': 'Tissue distribution of chloroquine, hydroxychloroquine, and ' 'desethylchloroquine in the rat', 'author': 'McChesney', 'doi-asserted-by': 'crossref', 'first-page': '501', 'journal-title': 'Toxicol Appl Pharmacol', 'key': '2020111907070828500_CIT0011', 'volume': '10', 'year': '1967'}, { 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2)', 'author': 'Yao', 'doi-asserted-by': 'crossref', 'journal-title': 'Clin Infect Dis', 'key': '2020111907070828500_CIT0012', 'year': '2020'}, { 'DOI': '10.1371/journal.pone.0074640', 'article-title': 'Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α ' 'and chemokine production by human lung parenchyma', 'author': 'Buenestado', 'doi-asserted-by': 'crossref', 'first-page': 'e74640', 'journal-title': 'PLoS One', 'key': '2020111907070828500_CIT0013', 'volume': '8', 'year': '2013'}, { 'DOI': '10.1371/journal.pctr.0020006', 'article-title': 'Randomized dose-ranging controlled trial of AQ-13, a candidate ' 'antimalarial, and chloroquine in healthy volunteers', 'author': 'Mzayek', 'doi-asserted-by': 'crossref', 'first-page': 'e6', 'journal-title': 'PLoS Clin Trials', 'key': '2020111907070828500_CIT0014', 'volume': '2', 'year': '2007'}, { 'article-title': 'Hydroxychloroquine in patients with COVID-19: an open-label, ' 'randomized, controlled trial', 'author': 'Tang', 'journal-title': 'medRxiv', 'key': '2020111907070828500_CIT0015'}], 'reference-count': 15, 'references-count': 15, 'relation': {}, 'resource': {'primary': {'URL': 'https://academic.oup.com/cid/article/71/16/2265/5831983'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [], 'subtitle': [], 'title': 'Chloroquine Inhibits the Release of Inflammatory Cytokines by Human Lung Explants', 'type': 'journal-article', 'volume': '71'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit